|
|
|
|
Breast Cancer Res Treat 2009,Dec,01;118(3):539-46; (PMID: 19609668)
Annual MRI screening is recommended as an adjunct to mammography for BRCA1 and BRCA2 mutation carriers. Prophylactic oophorectomy has been shown to decrease breast cancer risk in [...]
|
|
|
Ann Surg Oncol 2009,Dec,01;16(12):3380-7; (PMID: 19649554)
[...] in BRCA mutation carriers followed at a single institution. METHODS: A total of 54 women with BRCA1/2-associated breast cancer treated with BCS and whole breast radiotherapy were matched for age, tumor size, and time of surgery with 162 [...]
|
|
|
Am J Gastroenterol 2009,Sep,01;104(9):2175-81; (PMID: 19491823)
[...], 3 individuals were diagnosed with hereditary pancreatitis, 2 were Peutz-Jeghers patients, 3 were BRCA1 and 2 were BRCA2 mutation carriers with familial clustering of PC, and 1 individual had a p53 mutation.[...]
|
|
|
Int J Gynecol Cancer 2009,Aug,01;19(6):1022-8; (PMID: 19820363)
[...] received a median of 7.5 courses of PLD at 30 to 35 mg/m2 plus oxaliplatin at 70 mg/m2, and associations between BRCA1/2 and TP53 status and overall survival (OS) were determined. Thirty-eight had a short platinum-free interval (PFI; [...]
|
|
|
Breast Cancer Res Treat 2009,May,01;115(2):365-71; (PMID: 18661230)
[...]Multivariate analysis showed this was driven by the greater number of BRCA1/2 carriers in that group but was not related to screening recall. CONCLUSIONS: Practitioners' concerns about the high false positive rate of breast MRI may not be matched by actual psychological effects in most high-risk [...]
|
|
|
Breast Cancer Res Treat 2009,May,01;115(2):359-63; (PMID: 18649131)
BACKGROUND: Ten patients with breast cancer and a breast cancer susceptibility gene 1 (BRCA1) mutation, who presented with stages I to III breast cancer between December 2006 and 2007, were treated with four cycles of neoadjuvant [...]
|
|
|
Plast Reconstr Surg 2009,Jan,01;123(1):1-6; discussion 107-8; (PMID: 19116505)
BACKGROUND: Allogenic acellular dermal matrix can be used in single-stage, expander-based immediate and delayed breast reconstructions to provide inferolateral prosthesis coverage and reconstruction of the inframammary fold. Two allogenic dermal matrix products currently available, AlloDerm and DermaMatrix, differ in method of storage, cost, and intraoperative preparation.[...]
|
|
|
Hum Mol Genet 2008,May,01;17(9):1336-48; (PMID: 18204050)
The contribution of BRCA1 and BRCA2 to familial and non-familial forms of breast cancer has been difficult to accurately estimate because of the myriad of potential genetic and [...]
|
|
|
Hum Mol Genet 2008,May,01;17(9):1329-35; (PMID: 18204051)
[...] and ASPM in a Chinese population of 867 unrelated individuals. We demonstrate that a non-synonymous SNP (rs1057090, V761A in BRCA1 C-terminus (BRCT) domain) of MCPH1 other than the two known tag SNPs is significantly associated with cranial volume in Chinese males.[...]
|
|
|
Patient Educ Couns 2008,Jan,01;70(1):135-42; (PMID: 17988821)
[...] is the leading cause of gynecological death in the United States, and 14% of ovarian cancer cases are attributed to BRCA1/2 hereditary mutations. This study examined (1) change in subjective ovarian cancer risk in response to [...]
|
 1 2 3 4 5 6 
|
|
